SG11202005584TA - Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof - Google Patents

Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof

Info

Publication number
SG11202005584TA
SG11202005584TA SG11202005584TA SG11202005584TA SG11202005584TA SG 11202005584T A SG11202005584T A SG 11202005584TA SG 11202005584T A SG11202005584T A SG 11202005584TA SG 11202005584T A SG11202005584T A SG 11202005584TA SG 11202005584T A SG11202005584T A SG 11202005584TA
Authority
SG
Singapore
Prior art keywords
methods
chimeric receptors
multispecific chimeric
nkg2d domain
nkg2d
Prior art date
Application number
SG11202005584TA
Other languages
English (en)
Inventor
Xiaohu Fan
Jun Wang
Pingyan Wang
Qiuchuan Zhuang
Lian Ma
Original Assignee
Nanjing Legend Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotech Co Ltd filed Critical Nanjing Legend Biotech Co Ltd
Publication of SG11202005584TA publication Critical patent/SG11202005584TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464419—Receptors for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464429—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464436—Cytokines
    • A61K39/46444—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056—Lectin superfamily, e.g. CD23, CD72
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/15—Non-antibody based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202005584TA 2017-12-28 2018-12-28 Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof SG11202005584TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/119397 WO2019127215A1 (en) 2017-12-28 2017-12-28 Multispecific chimeric receptors comprising an nkg2d domain and methods of use thereof
PCT/CN2018/124978 WO2019129220A1 (en) 2017-12-28 2018-12-28 Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof

Publications (1)

Publication Number Publication Date
SG11202005584TA true SG11202005584TA (en) 2020-07-29

Family

ID=67063249

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202005584TA SG11202005584TA (en) 2017-12-28 2018-12-28 Multispecific chimeric receptors comprising nkg2d domain and methods of use thereof

Country Status (14)

Country Link
US (1) US20210363218A1 (zh)
EP (1) EP3732192A4 (zh)
JP (1) JP7379803B2 (zh)
KR (1) KR20200103703A (zh)
CN (3) CN114656569B (zh)
AU (1) AU2018396969A1 (zh)
BR (1) BR112020013211A2 (zh)
CA (1) CA3086932A1 (zh)
IL (1) IL275512A (zh)
MX (1) MX2020006818A (zh)
RU (1) RU2020120853A (zh)
SG (1) SG11202005584TA (zh)
TW (1) TW201930342A (zh)
WO (2) WO2019127215A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3056591A1 (en) 2017-03-27 2018-10-04 National University Of Singapore Stimulatory cell lines for ex vivo expansion and activation of natural killer cells
EP3749685A4 (en) * 2018-02-09 2021-12-22 National University of Singapore ACTIVATOR CHEMERIC RECEPTORS AND THEIR USES IN NATURAL KILLING CELL IMMUNOTHERAPY
WO2021219048A1 (zh) * 2020-04-30 2021-11-04 迈威(上海)生物科技股份有限公司 一种靶向nkg2a和pd-l1的双特异性抗体及应用
AU2021299573A1 (en) * 2020-07-03 2023-02-23 The Trustees Of Columbia University In The City Of New York Polyfunctional orthogonal protein chimeras
CN116194124A (zh) * 2020-07-31 2023-05-30 中外制药株式会社 包含表达嵌合受体的细胞的药物组合物
AU2022282266A1 (en) * 2021-05-24 2023-12-14 Kite Pharma, Inc. Nkg2d-based chimeric antgen receptor
CN117736335A (zh) * 2022-09-20 2024-03-22 深圳先进技术研究院 靶向间皮素和nkg2d配体的双靶向car-t细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001071005A2 (en) * 2000-03-24 2001-09-27 Micromet Ag Multifunctional polypeptides comprising a binding site to an epitope of the nkg2d receptor complex
US20130266551A1 (en) * 2003-11-05 2013-10-10 St. Jude Children's Research Hospital, Inc. Chimeric receptors with 4-1bb stimulatory signaling domain
AU2013221672B2 (en) * 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
JPWO2013180200A1 (ja) * 2012-05-30 2016-01-21 中外製薬株式会社 標的組織特異的抗原結合分子
EP2948544A4 (en) * 2013-01-28 2016-08-03 St Jude Childrens Res Hospital CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES
RU2764074C2 (ru) * 2014-08-28 2022-01-13 Байоатла, Ллк Условно активные химерные антигенные рецепторы для модифицированных т-клеток
KR20170100653A (ko) * 2014-12-31 2017-09-04 안트로제네시스 코포레이션 천연 킬러 세포를 사용하여 혈액학적 장애, 고형 종양, 또는 감염 질환을 치료하는 방법
TW201627322A (zh) * 2015-01-26 2016-08-01 宏觀基因股份有限公司 抗-ｄｒ５抗體和包括其ｄｒ５-結合結構域的分子
AU2016275030B2 (en) * 2015-06-10 2021-12-09 Nantkwest, Inc. Modified NK-92 cells for treating cancer
EP3331913A1 (en) * 2015-08-07 2018-06-13 Novartis AG Treatment of cancer using chimeric cd3 receptor proteins
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
EP3373952A4 (en) * 2015-11-10 2019-05-22 Fred Hutchinson Cancer Research Center NKG2D decoys
AU2016353231B2 (en) * 2015-11-13 2020-08-13 Dana-Farber Cancer Institute, Inc. An NKG2D-Ig fusion protein for cancer immunotherapy
CN105647873A (zh) * 2016-03-14 2016-06-08 紫程瑞生会(北京)生物技术发展有限公司 一种双特异性嵌合抗原受体基因修饰的自然杀伤细胞的制备方法及其试剂盒
EP3443002A4 (en) * 2016-04-14 2019-12-04 Bluebird Bio, Inc. RECOVERY ANTIGEN RECEPTOR SYSTEMS
CA3056439A1 (en) * 2017-03-27 2018-10-04 National University Of Singapore Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy
CN107326014B (zh) * 2017-07-31 2019-09-24 时力生物科技（北京）有限公司 一种双特异性嵌合抗原受体修饰的t淋巴细胞及其制备方法和应用

Also Published As

Publication number Publication date
BR112020013211A2 (pt) 2021-09-28
TW201930342A (zh) 2019-08-01
CN111836827B (zh) 2022-02-01
AU2018396969A1 (en) 2020-07-02
CA3086932A1 (en) 2019-07-04
RU2020120853A (ru) 2022-01-28
CN114656569B (zh) 2024-01-30
CN114656570A (zh) 2022-06-24
JP7379803B2 (ja) 2023-11-15
US20210363218A1 (en) 2021-11-25
CN111836827A (zh) 2020-10-27
JP2021508463A (ja) 2021-03-11
CN114656569A (zh) 2022-06-24
IL275512A (en) 2020-08-31
EP3732192A4 (en) 2022-05-04
WO2019129220A1 (en) 2019-07-04
KR20200103703A (ko) 2020-09-02
CN114656570B (zh) 2024-03-01
EP3732192A1 (en) 2020-11-04
WO2019127215A1 (en) 2019-07-04
MX2020006818A (es) 2021-01-08

Similar Documents

Publication Publication Date Title
IL262041A (en) Chimeric receptors and methods of using them
HK1259019A1 (zh) 抗pd1抗體及使用方法
HK1249405A1 (zh) 抗dll3嵌合抗原受體及其使用方法
IL255336A0 (en) Chimeric antigen receptors and methods of using them
ZA201905677B (en) Glycan-interacting compounds and methods of use
IL275512A (en) Multi-targeting chimeric receptors containing the NKG2D region and methods of using them
IL287407A (en) Chimeric receptors and methods of using them
IL252604A0 (en) Chimeric antigen receptors and their misuse
ZA201703471B (en) Anti-cldn chimeric antigen receptors and methods of use
EP3638300A4 (en) FIBRONECTIN-BINDING CHEMICAL ANTIGEN RECEPTORS AND METHODS OF USE
IL275070A (en) FCRN antibodies and methods of using them
IL283387A (en) Diarylhydantoin compounds and methods of use thereof
IL283782A (en) Analosomes and methods of use
HK1246194A1 (zh) 卡奇霉素構建體和使用方法
ZA202002144B (en) Antibodies and methods of use
EP3849663C0 (en) PYRIMIDINYL-HETEROARYLOXY-NAPHTHYL COMPOUNDS AND METHODS OF USE
GB201810835D0 (en) Methods of use
AU2016222891A1 (en) Anti-DLL3 chimeric antigen receptors and methods of use
AU2014903404A0 (en) Receptor dimerization domain and method of use